Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jeffrey Newcorn
Icahn School of Medicine at Mount Sinai, Department: Psychiatry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Shire Pharmaceuticals
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Dr. Jeffrey Newcorn (the Principal Investigator in this study) receives financial compensation as an advisory board member for Shire Pharmaceuticals (manufacturer of Adderall, a drug being used in this study).
Dr. Newcorn also receives financial compensation as a consultant or advisory board member from companies which either develop or assess medicines that may be used for the treatment of ADHD.
Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder
Childhood ADHD and comorbid oppositional defiant disorder (ODD) and conduct disorder (CD) are considered risk factors for subsequent substance abuse, and youth with both ADHD and ODD/CD are at greatest risk. However, the effects of treatment of ADHD with stimulant medications such as methylphenidate (MPH) and mixed amphetamine salts (MAS) on risk for substance abuse are poorly understood. We propose to use fMRI to study the effects of extended release mixed amphetamine salts (MAS?XR) in drug-na�ve youth 8-12 years at low risk (i.e., ADHD only) and high risk (i.e., ADHD + ODD/CD) for substance abuse on the brain reward system, to better understand the potential impact of these medications on an aspect of brain functioning which is thought to underlie vulnerability to substance abuse.
Filed on July 01, 2019.
Tell us what you know about Jeffrey Newcorn's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Jeffrey Newcorn filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jeffrey Newcorn | Icahn School of Medicine at Mount Sinai | Conflict of Interest | NLS | $20,000 - $39,999 |
| Jeffrey Newcorn | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Ironshore | $10,000 - $19,999 |
| Jeffrey Newcorn | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Shire | $5,000 - $9,999 |
| Jeffrey Newcorn | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Alcobra Ltd. | $5,000 - $9,999 |
| Jeffrey Newcorn | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Sunovion Pharmaceuticals | $5,000 - $9,999 |
| Jeffrey Newcorn | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Shire | $5,000 - $9,999 |
| Jeffrey Newcorn | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Sunovian Pharmaceuticals Inc. | $5,000 - $9,999 |
| Jeffrey Newcorn | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Alcobra Ltd | $0 - $4,999 |
| Jeffrey Newcorn | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Enzymotec | $0 - $4,999 |
| Jeffrey Newcorn | Icahn School of Medicine at Mount Sinai | Conflict of Interest | GencoSciences LLC | $0 - $4,999 |
| Jeffrey Newcorn | Icahn School of Medicine at Mount Sinai | Conflict of Interest | BioBDx | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.